August 4, 2023, marked a significant milestone in the field of maternal mental health as the FDA has approved zuranolone, marketed as Zurzuvae, a groundbreaking treatment for postpartum depression (PPD). This 14-day oral regimen, developed by Sage Therapeutics and Biogen Inc., demonstrated significant improvement in depressive symptoms in Phase III trials. Zurzuvae is the first daily pill option available, increasing accessibility and convenience for those in need.